ATE227292T1 - Herstellung von camptothecinderivaten durch intramolekulare cyclisierung - Google Patents
Herstellung von camptothecinderivaten durch intramolekulare cyclisierungInfo
- Publication number
- ATE227292T1 ATE227292T1 AT95918904T AT95918904T ATE227292T1 AT E227292 T1 ATE227292 T1 AT E227292T1 AT 95918904 T AT95918904 T AT 95918904T AT 95918904 T AT95918904 T AT 95918904T AT E227292 T1 ATE227292 T1 AT E227292T1
- Authority
- AT
- Austria
- Prior art keywords
- production
- intramolecular cyclization
- chem
- compound
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/237,081 US5491237A (en) | 1994-05-03 | 1994-05-03 | Intermediates in pharmaceutical camptothecin preparation |
PCT/US1995/005427 WO1995029919A1 (en) | 1994-05-03 | 1995-05-02 | Preparation of a camptothecin derivative by intramolecular cyclisation |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE227292T1 true ATE227292T1 (de) | 2002-11-15 |
Family
ID=22892263
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02014439T ATE289608T1 (de) | 1994-05-03 | 1995-05-02 | Herstellung von camptothecinderivaten durch intramolekulare cyclisierung |
AT95918904T ATE227292T1 (de) | 1994-05-03 | 1995-05-02 | Herstellung von camptothecinderivaten durch intramolekulare cyclisierung |
AT95917217T ATE260919T1 (de) | 1994-05-03 | 1995-05-02 | Zwischenprodukte für die herstellung von pharmazeutischem camptothecin |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02014439T ATE289608T1 (de) | 1994-05-03 | 1995-05-02 | Herstellung von camptothecinderivaten durch intramolekulare cyclisierung |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT95917217T ATE260919T1 (de) | 1994-05-03 | 1995-05-02 | Zwischenprodukte für die herstellung von pharmazeutischem camptothecin |
Country Status (10)
Country | Link |
---|---|
US (4) | US5491237A (de) |
EP (3) | EP0758333B1 (de) |
JP (2) | JPH09512558A (de) |
AT (3) | ATE289608T1 (de) |
AU (2) | AU2465195A (de) |
DE (3) | DE69532634T2 (de) |
DK (1) | DK0758335T3 (de) |
ES (3) | ES2219661T3 (de) |
HK (1) | HK1052687A1 (de) |
WO (2) | WO1995029917A2 (de) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6559309B2 (en) | 1996-11-01 | 2003-05-06 | Osi Pharmaceuticals, Inc. | Preparation of a camptothecin derivative by intramolecular cyclisation |
US6207832B1 (en) * | 1999-04-09 | 2001-03-27 | University Of Pittsburgh | Camptothecin analogs and methods of preparation thereof |
US6288072B1 (en) * | 1999-12-29 | 2001-09-11 | Monroe E. Wall | Camptothecin β-alanine esters with topoisomerase I inhibition |
EP1512413A3 (de) | 2001-01-16 | 2009-09-23 | Glaxo Group Limited | Pharmazeutische Mischung gegen Krebs, die ein 4-Chinazolinamin in Kombination mit einem anderen antineoplastischen Wirkstoff enthält |
US6809210B2 (en) | 2001-06-12 | 2004-10-26 | Lucent Technologies Inc. | Method of solvating a metal in an aromatic organic liquid |
US6593334B1 (en) | 2002-05-02 | 2003-07-15 | The University Of North Carolina At Chapel Hill | Camptothecin-taxoid conjugates as antimitotic and antitumor agents |
CZ299329B6 (cs) * | 2003-08-26 | 2008-06-18 | Pliva-Lachema A.S. | Zpusob výroby 7-ethyl-10-[ 4-(1-piperidino)-1-piperidino]karbonyloxykamptothecinu |
CZ299593B6 (cs) * | 2003-12-16 | 2008-09-10 | Pliva-Lachema A. S. | Zpusob výroby 7-ethyl-10-hydroxykamptothecinu |
US8492456B2 (en) * | 2004-02-09 | 2013-07-23 | Hewlett-Packard Development Company, L.P. | Ink compositions for ink-jet printing |
ATE531719T1 (de) * | 2005-02-22 | 2011-11-15 | Hoffmann La Roche | Neue synthese einer camptothecin-untereinheit |
TWI375678B (en) * | 2005-06-09 | 2012-11-01 | Yakult Honsha Kk | A method of preparation of a tricyclic ketone |
UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
UY30915A1 (es) | 2007-02-16 | 2008-09-02 | Smithkline Beecham Corp | Método de tratamiento de canceres |
US20110129550A1 (en) * | 2007-02-16 | 2011-06-02 | Connie Erickson-Miller | Cancer treatment method |
US20110160130A1 (en) * | 2007-02-16 | 2011-06-30 | Connie Erickson-Miller | Cancer treatment method |
PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
CN101888841B (zh) * | 2007-10-09 | 2012-09-26 | 宾夕法尼亚大学理事会 | 血小板生成素受体激动剂(TpoRA)杀死急性人骨髓样白血病细胞 |
US8697685B2 (en) | 2008-11-20 | 2014-04-15 | Glaxosmithkline Llc | Chemical compounds |
EP2400964A4 (de) | 2009-01-30 | 2012-08-01 | Glaxosmithkline Llc | Kristallines n-{(1-s)-2-amino-1-[(3-fluorphenyl)methyl]ethyl}-5-chlor-4-(4-chlor-1-methyl-1h-pyrazol-5-yl)-2-thiophencarboxamid hydrochlorid |
US8410095B2 (en) | 2009-05-20 | 2013-04-02 | Glaxosmithkline Llc | Thiazolopyrimidinone derivatives as PI3 kinase inhibitors |
CN101591342B (zh) * | 2009-07-03 | 2011-07-27 | 华东师范大学 | 用于喜树碱类化合物制备的关键中间体合成方法 |
US20110065698A1 (en) | 2009-08-26 | 2011-03-17 | Cylene Pharmaceuticals, Inc. | Novel protein kinase modulators |
BR112012024380A2 (pt) | 2010-03-25 | 2015-09-15 | Glaxosmithkline Llc | compostos químicos |
EA022623B1 (ru) | 2010-10-06 | 2016-02-29 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Производные бензимидазола в качестве ингибиторов pi3-киназ |
TWI505828B (zh) | 2010-12-20 | 2015-11-01 | 葛蘭素史克智慧財產(第二)有限公司 | 新穎醫藥組成物 |
SG11201402531XA (en) | 2011-11-22 | 2014-08-28 | Deciphera Pharmaceuticals Llc | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities |
KR20140117644A (ko) | 2012-01-31 | 2014-10-07 | 스미스클라인 비이참 (코르크) 리미티드 | 암을 치료하는 방법 |
MX2015006152A (es) | 2012-11-20 | 2016-01-20 | Genentech Inc | Compuestos de aminopirimidina como inhibidores de mutantes de egfr que contienen t7 9 0m. |
EP3400933A1 (de) | 2012-11-30 | 2018-11-14 | Novartis AG | Neuartige pharmazeutische trametinib zusammensetzung |
US20150342957A1 (en) | 2013-01-09 | 2015-12-03 | Glaxosmithkline Intellectual Property (No.2) Limited | Combination |
EP2943484B1 (de) | 2013-01-10 | 2017-10-25 | Glaxosmithkline Intellectual Property (No. 2) Limited | Fettsäuresynthasehemmer |
WO2015056180A1 (en) | 2013-10-15 | 2015-04-23 | Glaxosmithkline Intellectual Property (No.2) Limited | Indoline derivatives as inhibitors of perk |
US20160361309A1 (en) | 2014-02-26 | 2016-12-15 | Glaxosmithkline Intellectual Property (No.2) Limited | Methods of treating cancer patients responding to ezh2 inhibitor gsk126 |
WO2016055935A1 (en) | 2014-10-06 | 2016-04-14 | Glaxosmithkline Intellectual Property (No.2) Limited | Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist |
WO2016059602A2 (en) | 2014-10-16 | 2016-04-21 | Glaxo Group Limited | Methods of treating cancer and related compositions |
MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
WO2017025871A1 (en) | 2015-08-07 | 2017-02-16 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy comprising anti ctla-4 antibodies |
JP2019505476A (ja) | 2015-12-01 | 2019-02-28 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 組合せ処置およびその方法 |
WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
WO2017153952A1 (en) | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | 5-sulfamoyl-2-hydroxybenzamide derivatives |
EP3494140A1 (de) | 2016-08-04 | 2019-06-12 | GlaxoSmithKline Intellectual Property Development Ltd | Anti-icos- und anti-pd-1-antikörper-kombinationstherapie |
EP3548638A1 (de) | 2016-12-01 | 2019-10-09 | GlaxoSmithKline Intellectual Property Development Limited | Verfahren zur behandlung von krebs |
AU2018297656B2 (en) | 2017-07-05 | 2021-09-16 | Novartis Ag | Novel pharmaceutical composition |
TW201922721A (zh) | 2017-09-07 | 2019-06-16 | 英商葛蘭素史克智慧財產發展有限公司 | 化學化合物 |
WO2019053617A1 (en) | 2017-09-12 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | CHEMICAL COMPOUNDS |
MX2021009189A (es) | 2019-02-01 | 2021-11-12 | Glaxosmithkline Ip Dev Ltd | Belantamab mafodotin en combinación con pembrolizumab para el tratamiento del cáncer. |
CA3143211A1 (en) | 2019-06-26 | 2020-12-30 | Glaxosmithkline Intellectual Property Development Limited | Il1rap binding proteins |
WO2021018941A1 (en) | 2019-07-31 | 2021-02-04 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating cancer |
WO2021043961A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy |
WO2021046289A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and ipilimumab |
CN115038466A (zh) | 2020-01-28 | 2022-09-09 | 葛兰素史密斯克莱知识产权发展有限公司 | 联合治疗及其用途和方法 |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE152774C (de) * | ||||
US4399282A (en) * | 1979-07-10 | 1983-08-16 | Kabushiki Kaisha Yakult Honsha | Camptothecin derivatives |
DD152774A1 (de) * | 1980-08-25 | 1981-12-09 | Brunhilde Gorski | Verfahren zur abtrennung von palladium und technetium aus loesungen der kernbrennstoffwiederaufbereitung |
US4399276A (en) * | 1981-01-09 | 1983-08-16 | Kabushiki Kaisha Yakult Honsha | 7-Substituted camptothecin derivatives |
US4413118A (en) * | 1981-03-02 | 1983-11-01 | Merck & Co., Inc. | Process for removal of homogeneous catalyst group VIII metals from process streams |
US4473692A (en) * | 1981-09-04 | 1984-09-25 | Kabushiki Kaisha Yakult Honsha | Camptothecin derivatives and process for preparing same |
EP0220601B1 (de) * | 1985-10-21 | 1991-12-11 | Daiichi Seiyaku Co., Ltd. | Pyranoindolizinderivate und Verfahren zu ihrer Herstellung |
JPS6314824A (ja) * | 1986-07-04 | 1988-01-22 | Tanaka Kikinzoku Kogyo Kk | 貴金属元素の回収方法 |
JPS6333355A (ja) * | 1986-07-29 | 1988-02-13 | Mitsui Toatsu Chem Inc | シスチンの精製方法 |
US4981968A (en) * | 1987-03-31 | 1991-01-01 | Research Triangle Institute | Synthesis of camptothecin and analogs thereof |
US5227380A (en) * | 1987-03-31 | 1993-07-13 | Research Triangle Institute | Pharmaceutical compositions and methods employing camptothecins |
US5106742A (en) * | 1987-03-31 | 1992-04-21 | Wall Monroe E | Camptothecin analogs as potent inhibitors of topoisomerase I |
US5053512A (en) * | 1987-04-14 | 1991-10-01 | Research Triangle Institute | Total synthesis of 20(S) and 20(R)-camptothecin and compthothecin derivatives |
US5244903A (en) * | 1987-03-31 | 1993-09-14 | Research Triangle Institute | Camptothecin analogs as potent inhibitors of topoisomerase I |
US4894456A (en) * | 1987-03-31 | 1990-01-16 | Research Triangle Institute | Synthesis of camptothecin and analogs thereof |
US5122526A (en) * | 1987-03-31 | 1992-06-16 | Research Triangle Institute | Camptothecin and analogs thereof and pharmaceutical compositions and method using them |
US5049668A (en) * | 1989-09-15 | 1991-09-17 | Research Triangle Institute | 10,11-methylenedioxy-20(RS)-camptothecin analogs |
US5122606A (en) * | 1987-04-14 | 1992-06-16 | Research Triangle Institute | 10,11-methylenedioxy camptothecins |
US5180722A (en) * | 1987-04-14 | 1993-01-19 | Research Triangle Institute | 10,11-methylenedioxy-20(RS)-camptothecin and 10,11-methylenedioxy-20(S)-camptothecin analogs |
US4943579A (en) * | 1987-10-06 | 1990-07-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Water soluble prodrugs of camptothecin |
US5004758A (en) * | 1987-12-01 | 1991-04-02 | Smithkline Beecham Corporation | Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells |
US4871855A (en) * | 1988-01-11 | 1989-10-03 | Massachusetts Institute Of Technology | Ligand-accelerated catalytic asymmetric dihydroxylation using dihydroquinidine and dihydroquinidine esters as ligands |
US5227543A (en) * | 1988-01-11 | 1993-07-13 | Massachusetts Institute Of Technology | Facilitation of turnover in the ADH by additives which catalyze the hydrolysis of the OS(VI) glycolate esters |
US5126494A (en) * | 1988-01-11 | 1992-06-30 | Massachusetts Institute Of Technology | Methods for catalytic asymmetric dihydroxylation of olefins |
US4965364A (en) * | 1988-02-23 | 1990-10-23 | Massachusetts Institute Of Technology | Ligand-accelerated catalytic asymmetric dihydroxylation |
US5260461A (en) * | 1988-01-11 | 1993-11-09 | Massachusetts Institute Of Technology | Ligands for ADH: cinchona alkaloids and moderately sized organic substituents linked through a planar aromatic spacer group |
EP0395729B1 (de) * | 1988-01-11 | 1995-09-27 | Massachusetts Institute Of Technology | Durch komplexmittel beschleunigte katalytische asymmetrische dihydroxylierung |
JPH0615547B2 (ja) * | 1988-01-20 | 1994-03-02 | 株式会社ヤクルト本社 | 新規なカンプトテシン誘導体 |
ES2165346T3 (es) * | 1989-09-15 | 2002-03-16 | Res Triangle Inst | Analogos de 10,11-metilendioxi-20(rs)-camptotecina y 10,11-metilendioxi-20(s)-camptotecina. |
US5099047A (en) * | 1989-11-17 | 1992-03-24 | Mitsubishi Kasei Corporation | Method for recovering a group viii metal solid complex and hydroformylation method |
EP0555347A4 (en) * | 1990-10-31 | 1995-01-11 | Smithkline Beecham Corp | Substituted indolizino 1,2-b)quinolinones |
US5247089A (en) * | 1990-12-20 | 1993-09-21 | North Carolina State University | Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs |
US5254690A (en) * | 1990-12-20 | 1993-10-19 | North Carolina State University | Alkoxymethylpyridine d-ring intermediates useful for the synthesis of camptpthecin and camptothecin analogs |
US5264579A (en) * | 1990-12-20 | 1993-11-23 | North Carolina State University | D ring intermediates for the synthesis of camptothecin and camptothecin analogs |
US5191082A (en) * | 1990-12-20 | 1993-03-02 | North Carolina State University | Camptothecin intermediate and method of making camptothecin intermediates |
US5315007A (en) * | 1990-12-20 | 1994-05-24 | North Carolina State University | Process for making DE ring intermediates for the synthesis of camptothecin and camptothecin analogs |
US5212317A (en) * | 1990-12-20 | 1993-05-18 | North Carolina State University | Methods and intermediates for the assymmetric synthesis of camptothecin and camptothecin analogs |
US5243050A (en) * | 1990-12-20 | 1993-09-07 | North Carolina State University | Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs |
US5258516A (en) * | 1990-12-20 | 1993-11-02 | Nc State University | Optically pure D,E ring intermediates useful for the synthesis of camptothecin and camptothecin analogs |
US5162532A (en) * | 1990-12-20 | 1992-11-10 | North Carolina State University | Intermediates and method of making camptothecin and camptothecin analogs |
US5200524A (en) * | 1990-12-20 | 1993-04-06 | North Carolina State University | Camptothecin intermediates and method of making same |
WO1992020677A1 (en) * | 1991-05-13 | 1992-11-26 | Massachusetts Institute Of Technology | Heterocyclic chiral ligands and method for catalytic asymmetric dihydroxylation of olefins |
DK0540099T3 (da) * | 1991-10-29 | 1996-06-17 | Glaxo Wellcome Inc | Vandopløselige camptothecinderivater |
EP0556585A3 (de) * | 1992-01-24 | 1993-09-01 | Takeda Chemical Industries, Ltd. | Kondensierte Camptotherinderivate, ihre Herstellung und ihre Verwendung als Antitumormittel |
AU3611093A (en) * | 1992-02-21 | 1993-09-13 | Smithkline Beecham Corporation | Substituted furo(3',4':6,7)indolizino(1,2-b)quinolinones |
CA2142831A1 (en) * | 1992-08-21 | 1994-03-03 | Arthur B. Pardee | Treatment of human viral infections |
US5342947A (en) * | 1992-10-09 | 1994-08-30 | Glaxo Inc. | Preparation of water soluble camptothecin derivatives |
US5479108A (en) * | 1992-11-25 | 1995-12-26 | David Cheng | Method and apparatus for handling wafers |
AP9300587A0 (en) * | 1992-11-12 | 1995-05-05 | Glaxo Inc | Water soluble camptothecin derivatives. |
WO1997016454A1 (en) * | 1995-11-02 | 1997-05-09 | Glaxo Wellcome Inc. | Method for preparing camptothecin derivatives |
-
1994
- 1994-05-03 US US08/237,081 patent/US5491237A/en not_active Expired - Lifetime
-
1995
- 1995-05-02 DK DK95918904T patent/DK0758335T3/da active
- 1995-05-02 ES ES95917217T patent/ES2219661T3/es not_active Expired - Lifetime
- 1995-05-02 JP JP7528481A patent/JPH09512558A/ja not_active Ceased
- 1995-05-02 WO PCT/US1995/005425 patent/WO1995029917A2/en active IP Right Grant
- 1995-05-02 US US08/732,435 patent/US5840898A/en not_active Expired - Fee Related
- 1995-05-02 DE DE69532634T patent/DE69532634T2/de not_active Expired - Fee Related
- 1995-05-02 AT AT02014439T patent/ATE289608T1/de not_active IP Right Cessation
- 1995-05-02 AT AT95918904T patent/ATE227292T1/de not_active IP Right Cessation
- 1995-05-02 EP EP95917217A patent/EP0758333B1/de not_active Expired - Lifetime
- 1995-05-02 DE DE69534029T patent/DE69534029T2/de not_active Expired - Fee Related
- 1995-05-02 AU AU24651/95A patent/AU2465195A/en not_active Abandoned
- 1995-05-02 JP JP7528482A patent/JPH09512559A/ja active Pending
- 1995-05-02 US US08/737,032 patent/US6063923A/en not_active Expired - Fee Related
- 1995-05-02 EP EP02014439A patent/EP1254908B9/de not_active Expired - Lifetime
- 1995-05-02 AU AU23816/95A patent/AU2381695A/en not_active Abandoned
- 1995-05-02 WO PCT/US1995/005427 patent/WO1995029919A1/en active IP Right Grant
- 1995-05-02 DE DE69528762T patent/DE69528762T2/de not_active Expired - Fee Related
- 1995-05-02 ES ES02014439T patent/ES2238523T3/es not_active Expired - Lifetime
- 1995-05-02 AT AT95917217T patent/ATE260919T1/de not_active IP Right Cessation
- 1995-05-02 EP EP95918904A patent/EP0758335B1/de not_active Expired - Lifetime
- 1995-05-02 ES ES95918904T patent/ES2188661T3/es not_active Expired - Lifetime
-
2000
- 2000-04-19 US US09/552,214 patent/US6462196B1/en not_active Expired - Fee Related
-
2003
- 2003-05-05 HK HK03103188A patent/HK1052687A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DK0758335T3 (da) | 2003-03-17 |
DE69532634T2 (de) | 2005-03-10 |
WO1995029919A1 (en) | 1995-11-09 |
ES2238523T3 (es) | 2005-09-01 |
AU2381695A (en) | 1995-11-29 |
DE69534029D1 (de) | 2005-03-31 |
JPH09512558A (ja) | 1997-12-16 |
ATE260919T1 (de) | 2004-03-15 |
DE69528762D1 (de) | 2002-12-12 |
DE69532634D1 (de) | 2004-04-08 |
EP0758333A1 (de) | 1997-02-19 |
US6462196B1 (en) | 2002-10-08 |
ES2219661T3 (es) | 2004-12-01 |
JPH09512559A (ja) | 1997-12-16 |
US5491237A (en) | 1996-02-13 |
WO1995029917A3 (en) | 1995-12-28 |
AU2465195A (en) | 1995-11-29 |
DE69528762T2 (de) | 2003-07-17 |
US5840898A (en) | 1998-11-24 |
EP0758335B1 (de) | 2002-11-06 |
WO1995029917A2 (en) | 1995-11-09 |
HK1052687A1 (en) | 2003-09-26 |
EP0758335A1 (de) | 1997-02-19 |
ATE289608T1 (de) | 2005-03-15 |
DE69534029T2 (de) | 2006-01-12 |
EP1254908B1 (de) | 2005-02-23 |
ES2188661T3 (es) | 2003-07-01 |
EP1254908A1 (de) | 2002-11-06 |
EP1254908B9 (de) | 2005-09-21 |
EP0758333B1 (de) | 2004-03-03 |
US6063923A (en) | 2000-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69528762D1 (de) | Herstellung von camptothecinderivaten durch intramolekulare cyclisierung | |
NO303574B1 (no) | Ny fremgangsmÕte for fremstilling av 9-amino-6-demetyl-6-deoksytetracykliner | |
ATE294182T1 (de) | Zwischenprodukte zur herstellung von camptothecin und analogen | |
PL328726A1 (en) | Novel tricycle compounds, method of obtaining them and their applications | |
ATE113281T1 (de) | Pyrazol-derivate, verfahren zu deren herstellung und anwendung. | |
DE69231815T2 (de) | Verfahren zur Herstellung von Cephalosporinen und Zwischenprodukte in diesem Verfahren | |
DE3576952D1 (de) | Verfahren zur herstellung von 4-phenyl-pyrrol-derivaten. | |
DE3864636D1 (de) | Amidverbindungen, verfahren zu ihrer herstellung und zusammensetzung zur aktivierung gastromotorischer funktionen. | |
DE3851999D1 (de) | Verfahren zur Herstellung von Sulfonylharnstoff-Derivaten. | |
DE69521012D1 (de) | Verfahren zur Herstellung von 1-(4,5-Dihydro)2-thiazolyl-3-Azetidinthiolderivaten | |
DE3852506T2 (de) | Verfahren zur Herstellung von Halogensulfonyl-substituierten Pyridinen. | |
DE69714749T2 (de) | Verfahren zur herstellung von 3-amino-2-hydroxy-1-propylethern | |
ATE165824T1 (de) | Verfahren zur herstellung von 2-perfluoroalkyl-3- oxazolin-5-one | |
ATE224393T1 (de) | Verfahren zur herstellung von cephalosporinen und zwischenverbindungen in diesem verfahren | |
ATE311382T1 (de) | Verfahren zur herstellung von 2-carbamoyl- pyridinen | |
DE69733716D1 (de) | Verfahren zur herstellung von imidazolderivaten | |
DE69427100T2 (de) | Herstellung von Beta-lactamverbindungen und Zwischenprodukte | |
ATE329917T1 (de) | 1h-pyrrolo 1,2-bö 1,2,4ötriazolederivate, zwischenprodukte und verfahren zur herstellung von 1h-1,2,4,-triazol-5-yl essigsäureesterderivate | |
ATE206109T1 (de) | Verfahren zur herstellung von carbamoylmethylharnstoff-derivaten | |
ATE228993T1 (de) | Verfahren zur herstellung von 1,1,1-trifluoro-2- aminoalkane |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0758335 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |